Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Sunitinib is a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor
effects as well as antiangiogenetic activity. Preclinical and clinical data for Sunitinib and
data about angiogenesis and growth regulation in melanoma suggest the activity of Sunitinib
in melanoma. This study will investigate the efficacy, safety and tolerability of Sunitinib
as palliative treatment in chemo-refractory metastatic melanoma.